Compare Cardinal Health Inc (CAH) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Lockheed Martin Corporation — how do they compare? Cardinal Health Inc trades at $237.28 (market cap $55.88B), while Lockheed Martin Corporation trades at $606.55 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 2.5× Cardinal Health Inc's market cap, and Lockheed Martin Corporation pays the higher dividend (2.31%). Which is the better fit depends on your goals.
| CAH | LMT | |
|---|---|---|
Market Cap | $55.88B | $137.96B |
Sector | Health | Industrials |
52-Week High | $240.26 | $676.70 |
52-Week Low | $146.04 | $431.56 |
Enterprise Value | $59.91B | $154.71B |
Dividend Yield | 0.86% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $236.87, down 0.13% on the day, near its 52-week high. The stock shows strong momentum with four consecutive quarterly EPS beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Technical indicators are bullish overall, with moving averages supporting upward trends. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%.
Outlook remains positive driven by robust pharmaceutical demand and optimistic FY2027 guidance. Key risks include high debt levels and thin profit margins. Analysts maintain a bullish consensus with a $266.43 price target, representing 12.5% upside. The stock presents a growth opportunity but requires monitoring of margin pressures and cash flow volatility.
Lockheed Martin (LMT) trades at $601.99, down 0.19% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a record $230.4 billion backlog (Seeking Alpha, 2026-08-04), revenue growth to $75.05 billion in 2025, and a net income margin of 8.16%. Recent news highlights major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, 2026-08-11), supporting long-term growth.
The outlook for LMT is positive, driven by expanding defense budgets and execution on its backlog, though risks include earnings misses and debt levels. Analysts project a consensus price target of $608, with 57% recommending buy. The stock's valuation metrics, such as a P/E of 22.04, appear reasonable given growth prospects, but investors should monitor contract execution and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
